{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T08:30:55Z","timestamp":1783153855372,"version":"3.54.6"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,6,5]],"date-time":"2011-06-05T00:00:00Z","timestamp":1307232000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1007\/s00216-011-5126-9","type":"journal-article","created":{"date-parts":[[2011,6,4]],"date-time":"2011-06-04T01:02:12Z","timestamp":1307149332000},"page":"1013-1021","source":"Crossref","is-referenced-by-count":33,"title":["Development and validation of an HPLC\u2013UV detection assay for the determination of rufinamide in human plasma and saliva"],"prefix":"10.1007","volume":"401","author":[{"given":"Iolanda","family":"Mazzucchelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Rapetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Fattore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,6,5]]},"reference":[{"key":"5126_CR1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nurt.2006.11.006","volume":"4","author":"S Arroyo","year":"2007","unstructured":"Arroyo S (2007) Rufinamide. Neurotherapeutics 4:155\u2013162","journal-title":"Neurotherapeutics"},{"key":"5126_CR2","volume-title":"The treatment of epilepsy","author":"V Biton","year":"2009","unstructured":"Biton V (2009) In: Shorvon S, Perucca E, Engel J Jr (eds) The treatment of epilepsy, 3rd edn. Wiley Blackwell Publishing, Chichester","edition":"3"},{"key":"5126_CR3","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1111\/j.1742-1241.2006.01173.x","volume":"60","author":"A Cheng-Hakimian","year":"2006","unstructured":"Cheng-Hakimian A, Anderson GD, Miller JW (2006) Rufinamide: pharmacology, clinical trials, and role in clinical practice. Int J Clin Pract 60:1497\u20131501","journal-title":"Int J Clin Pract"},{"key":"5126_CR4","volume-title":"Epilepsy. A comprehensive textbook","author":"T Glauser","year":"2007","unstructured":"Glauser T, Bialer M (2007) In: Engel J Jr, Pedley T (eds) Epilepsy. A comprehensive textbook, 2nd edn. Lippincott Williams & Wilkins, Philadelphia","edition":"2"},{"key":"5126_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1535-7511.2009.01336.x","volume":"10","author":"JW Wheless","year":"2010","unstructured":"Wheless JW, Vazquez B (2010) Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 10:1\u20136","journal-title":"Epilepsy Curr"},{"key":"5126_CR6","unstructured":"European Medicine Agency (EMEA) (2004) Register of designated orphan medicinal products. http:\/\/ec.europa.eu\/enterprise\/pharmaceuticals\/register\/orphreg.htm"},{"key":"5126_CR7","unstructured":"Food and Drug Administration (FDA) (2004) Cumulative list of all orphan designated products. http:\/\/www.fda.gov\/orphan\/designat\/list.xls"},{"key":"5126_CR8","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1345\/aph.1M679","volume":"44","author":"CS Wisniewski","year":"2010","unstructured":"Wisniewski CS (2010) Rufinamide: a new antiepileptic medication for the treatment of seizure associated with Lennox\u2013Gastaut syndrome. Ann Pharmacother 44:658\u2013667","journal-title":"Ann Pharmacother"},{"key":"5126_CR9","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","volume":"122","author":"G Kluger","year":"2010","unstructured":"Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S (2010) Adjunctive rufinamide in Lennox\u2013Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 122:202\u2013208","journal-title":"Acta Neurol Scand"},{"key":"5126_CR10","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","volume":"49","author":"E Perucca","year":"2008","unstructured":"Perucca E, Cloyd J, Critchley D, Fuseau E (2008) Rufinamide: clinical pharmacokinetics and concentration\u2013response relationships in patients with epilepsy. Epilepsia 49:1123\u20131141","journal-title":"Epilepsia"},{"key":"5126_CR11","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/bmc.1130060606","volume":"6","author":"LA Brunner","year":"1992","unstructured":"Brunner LA, Powell ML (1992) An automated method for the determination of a new potential antiepileptic agent (CGP 33101) in human plasma using high performance liquid chromatography. Biomed Chromatogr 6:278\u2013282","journal-title":"Biomed Chromatogr"},{"key":"5126_CR12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0378-4347(95)00026-F","volume":"667","author":"MC Rouan","year":"1995","unstructured":"Rouan MC, Souppart C, Alif L, Moes D, Lecaillon JB, Godbillon J (1995) Automated analysis of a novel anti-epileptic compound, CGP 33101, and its metabolite, CGP 47292, in body fluids by high-performance liquid chromatography and liquid\u2013solid extraction. J Chromatogr B Biomed Appl 667:307\u2013313","journal-title":"J Chromatogr B Biomed Appl"},{"key":"5126_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jchromb.2009.11.039","volume":"878","author":"M Contin","year":"2010","unstructured":"Contin M, Mohamed S, Candela C, Albani F, Riva R, Baruzzi A (2010) Simultaneous HPLC\u2013UV analysis of rufinamide, zonisamide, lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in deproteinized plasma of patients with epilepsy. J Chromatogr B Analyt Technol Biomed Life Sci 878:461\u2013465","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"5126_CR14","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jpba.2010.07.015","volume":"54","author":"G Marca La","year":"2010","unstructured":"La Marca G, Malvagia S, Filippi L, Innocenti M, Rosati A, Falchi M, Pellacani S, Moneti G, Guerrini R (2010) Rapid assay of rufinamide in dried blood spots by a new liquid chromatography\u2013tandem mass spectrometric method. J Pharm Biomed Anal 54:192\u2013197","journal-title":"J Pharm Biomed Anal"},{"key":"5126_CR15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","volume":"33","author":"TW May","year":"2011","unstructured":"May TW, Boor R, Rambeck B, J\u00fcrgens U, Korn-Merker E, Brandt C (2011) Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age and comedication. Ther Drug Monit 33:214\u2013221","journal-title":"Ther Drug Monit"},{"key":"5126_CR16","unstructured":"Food and Drug Administration (2001) Guidance for industry: bioanalytical method validation, Rockville. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070107.pdf"},{"key":"5126_CR17","unstructured":"ICH Harmonized Tripartite Guideline (2005) International conference on harmonization of technical requirements for registration of pharmaceutical for human use. Validation of analytical procedures: text and methodology Q2 (R1) http:\/\/www.bioforum.org.il\/Uploads\/Editor\/karen\/q2_r1_step4.pdf"},{"key":"5126_CR18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00003088-199936060-00006","volume":"36","author":"H Liu","year":"1999","unstructured":"Liu H, Delgado MR (1999) Therapeutic drug concentration monitoring using saliva samples. Focus on anticonvulsants. Clin Pharmacokinet 36:453\u2013470","journal-title":"Clin Pharmacokinet"},{"key":"5126_CR19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/clinchem\/23.2.157","volume":"23","author":"MG Horning","year":"1977","unstructured":"Horning MG, Brown L, Nowlin J, Lertratanangkoon K, Kellaway P, Zion TE (1977) Use of saliva in therapeutic drug monitoring. Clin Chem 23:157\u2013164","journal-title":"Clin Chem"},{"key":"5126_CR20","first-page":"147","volume":"27","author":"OH Drummer","year":"2006","unstructured":"Drummer OH (2006) Drug testing in oral fluid. Clin Biochem Rev 27:147\u2013159","journal-title":"Clin Biochem Rev"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-011-5126-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-011-5126-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-011-5126-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T16:05:38Z","timestamp":1637769938000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-011-5126-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,5]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["5126"],"URL":"https:\/\/doi.org\/10.1007\/s00216-011-5126-9","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6,5]]}}}